<DOC>
	<DOCNO>NCT02684760</DOCNO>
	<brief_summary>PF-06651600 develop treatment inflammatory bowel disease . This study test bioavailability solid dose formulation PF-06651600 compare oral solution formulation fast condition effect high fat meal bioavailability solid dose formulation PF-06651600 healthy subject . Safety tolerability tablet oral solution formulation PF-06651600 assess fast feed condition .</brief_summary>
	<brief_title>Bioavailability Study Of PF-06651600 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male/female subject 18 55 year old , inclusive . Females must nonchild bear potential . BMI 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Prior history chicken pox . Evidence personally sign date informed consent document . Willing able comply schedule visit , treatment plan , lab test study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , GI , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male . Screening blood pressure &gt; 140/90 mm Hg . Screening laboratory abnormality define protocol . Unwilling unable comply Lifestyle Guidelines define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>